

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Molbio Diagnostics adds Truenat H3N2/H1N1 test to respiratory disease portfolio

03 April 2023 | News

A chip-based RT-PCR test that will detect and quantitatively diagnose H3N2/H1N1 in a single test with a sample-to-result time of one hour



Goa-based Molbio Diagnostics has launched the Truenat H3N2/H1N1 for differential diagnosis of the H3N2 and H1N1 virus. The test is approved by the Central Drugs Standard Control Organization (CDSCO) and can provide sample-to-result in an hour's time.

Truenat H3N2/H1N1 is the first point-of-care Real-Time PCR test that aids in the confirmatory diagnosis of Influenza infections. The test will work on the existing Truenat machines that are deployed across over 3500 primary and community healthcare centres and over 1200 private labs and hospitals across India, making it possible for patients to obtain a quick diagnosis at all levels of the healthcare chain.

India is currently seeing a surge in influenza viral infections due to H3N2 and H1N1. The viruses that spread through the air, have the ability for sustained human-to-human transmission, which can potentially cause an influenza pandemic.

Commenting on the launch, Sriram Natarajan, CEO, Founder, and Director of Molbio Diagnostics, said, "The launch of Truenat H3N2/H1N1 further strengthens Molbio's product portfolio by providing complete testing solutions for respiratory illnesses. The multi-disease testing capability of the Truenat platform keeps healthcare facilities prepared to combat all kinds of pandemics and disease outbreaks at early stage. Going forward, Molbio will continue to bring innovative solutions for better patient management and appropriate treatment of the disease."